This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Affymax

BOSTON ( TheStreet) -- Affymax (AFFY) and the outlook for next week's FDA advisory panel meeting kicks off this week's Biotech Stock Mailbag.

Calvin C. writes, "I really appreciate your work. I have one request from you as an avid fan of your blogs: Could you blog about the upcoming FDA panel meeting regarding Affymax's peginesatide on Dec. 7th? The data look great so I and many other investors would be very interested in such a blog! Thanks!"

Yes, I'll be live-blogging the Affymax FDA advisory panel meeting on Dec. 7. Before the panel, be aware (especially if you're trading the stock) that FDA will release its review of the peginesatide data on the morning of Monday, Dec. 5. You'll be able to find the FDA's peginesatide briefing documents here.

"Great" isn't the adjective I'd use to characterize the peginesatide data. "Adequate" is pretty much as far as I'd go -- and that might be too optimistic. Don't be surprised if the FDA's peginesatide review Monday reads negative (briefing documents are almost always critical.) The outcome of Wednesday's expert panel is a tossup; Wall Street's biotech buy-side sentiment leans negative.

Peginesatide is an erythropoiesis-stimulating agent (ESA), which like other ESAs ( Amgen's (AMGN) Epogen and Aranesp and Johnson & Johnson's (JNJ) Procrit) treat anemia by stimulating the body to produce red blood cells. Peginesatide is dosed once a month, which makes it more convenient that other ESAs.

Affymax and its partner Takeda are seeking FDA approval of peginesatide for the treatment of anemia in patients with chronic kidney disease. Four phase III clinical studies were conducted: The "Emerald" studies in patients with end-stage kidney disease who are on dialysis; and the "Pearl" studies in less-sick kidney disease patients who are not on dialysis.

Overall, the four phase III studies met their primary efficacy endpoints, which was to measure the mean change in hemoglobin levels from baseline to the end of the study.

Peginesatide was non-inferior compared to currently marketed ESAs, which is the statistical way of saying peginesatide was functionally equivalent to the other ESAs.

Across all four studies combined, peginesatide was also statistically non-inferior to the other ESAs for safety, measured by a cardiovascular composite safety endpoint (CSE), which included death, heart attack, stroke and other heart-related safety problems.

That's the good news. The following is where the peginesatide data get a bit hairy:

Problems arose when Affymax analyzed the two sets of phase III studies separately. In the non-dialysis "Pearl" studies, patients treated with peginesatide reported a higher rate of cardiovascular safety events (21.6%) compared to patients treated with other ESAs (17.1%). From a statistical perspective, the relative risk of having a heart-related safety problem was actually quite high for peginesatide compared to the other ESAs.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ONXX $0.00 0.00%
DNDN $0.06 -6.02%
CTIC $2.38 0.00%
AFFY $0.15 0.00%
CELG $123.35 0.00%


DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs